RDIF and ChemRar present Avifavir to Latin American & Caribbean representatives
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, supported by the Russian Embassy in Guatemala held a video conference on July 10, 2020 with representatives of Latin American and Caribbean states to present the first Russian anti-COVID drug Avifavir.
The regions are now facing an outbreak of coronavirus infection and all effective tools to combat coronavirus are in demand from the government agencies and medical institutions in those countries.
Almost 1,500 representatives from Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Peru, El Salvador, Uruguay and Venezuela, H.E. President of the Central American Parliament Nadia De León Torres, members of Pan-American Medical Association, Latin American Parliament participated in the conference.
The conference was arranged in partnership with Bering-Bellingshausen Institute for the Americas — a non-profit organization promoting dialogue of politicians, businessmen, journalists, scientists from Russia and the CIS countries with colleagues from the Americas.
Representatives from RDIF and ChemRar Group provided conference participants with information for using Avifavir in coronavirus therapy and its advantages compared to other drugs currently in use around the world to combat the pandemic. Following the conference agreements were reached to continue dialogues with representatives of Latin American states around the supply of Avifavir.
Avifavir is the first clinically proven and registered drug in Russia against coronavirus. It is also the first Favipiravir-based drug in the world approved for treatment of COVID-19. On May 29, 2020, Avifavir received a registration certificate from Russia’s Ministry of Health and on June 3, 2020, the Ministry of Health included Avifavir in the latest seventh edition of the guidelines for the prevention, diagnosis and treatment of new coronavirus infection COVID-19. Avifavir has proven effective in clinical trials, disrupting the reproduction mechanisms of coronavirus.
Avifavir delivers best results when used at the early and middle stages of infection. As a result, RDIF has asked to the Ministry of Health of the Russian Federation to allow the use of Avifavir by outpatients who receive therapy at home.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
“Avifavir is one of the first drugs to be created globally in the fight against coronavirus that has proven effective. RDIF and ChemRar have already exported it to Belarus and Kazakhstan, and negotiations are underway with countries in the Middle East and Asia. The video conference with almost 1,500 representatives from across Latin America today confirmed the high levels of foreign interest in Avifavir. We wish to thank all the conference’s participants and are ready to work in partnership to export the drug and support Latin American states in their fight against the pandemic”.
Nadia De León Torres, President of the Central American Parliament, said:
“We hope that this round-table will be of a great benefit to our regions, in Latin America and the world. I’d like to make a special thanks to the Russian Direct Investment Fund and the Russian Embassy to Guatemala that have been able to present and promote this first efficient drug in the Central American region so that we are in the vanguard of scientific discoveries. We stand united and hope to cooperate with the Russian Federation in order to defeat COVID-19”.
Russian Direct Investment Fund (RDIF) is Russia’s sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at www.rdif.ru
ChemRar Group unites R&D service and investment companies in the field of innovative pharmaceuticals for the development and commercialization of innovative medicines, diagnostics, preventive care and new treatments of life-threatening diseases in Russia and abroad. Further information can be found at http://en.chemrar.ru/
For additional information contact:
Mobile +7 9262067871